Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 10/20 | 0.66 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.56 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12171630 | 0.94 | HPSE (0.60) | HPSEHSPD1HSPE1HDAC6RAB9A | |
| SCHEMBL4886394 | 0.92 | HPSE (0.63) | HPSEHSPD1HSPE1L3MBTL1KDM4E | |
| SCHEMBL1675525 | 0.90 | HDAC6 (0.63) | HPSEHSPD1HSPE1HDAC6KDM4E | |
| SCHEMBL1675394 | 0.89 | HDAC6 (0.57) | HPSEHSPD1HSPE1HDAC6KDM4E | |
| SCHEMBL1675639 | 0.89 | TTR (0.56) | HPSEHSPD1HSPE1KMOL3MBTL1 | |
| SCHEMBL1675372 | 0.89 | HDAC6 (0.65) | HPSEHDAC6GAAL3MBTL1KDM4E | |
| SCHEMBL1675435 | 0.89 | HPSE (0.62) | HPSEHSPD1HSPE1HDAC6L3MBTL1 | |
| SCHEMBL1675379 | 0.89 | HDAC6 (0.61) | HPSEHSPD1HSPE1HDAC6 | |
| SCHEMBL2242694 | 0.88 | CASP3 (0.60) | HPSEHSPD1HSPE1HDAC6KDM4E | |
| SCHEMBL1675466 | 0.87 | HPSE (0.64) | HPSEHDAC6KDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | claimed |
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2011-04-14 | — | — | US | claimed |
| WO-2009151546-A2 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8633019-B2 | Methods for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2011-04-14 | — | — | US | disclosed |
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2011-04-14 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2009151546-A2 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151546-A2 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, NSUN2, SNRPB2 | HPSE 2578/4885HSPD1 1324/4885HSPE1 1297/4885 |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | HPSE 2113/4885HSPD1 194/4885HSPE1 172/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | HPSE 1969/4885HSPD1 175/4885HSPE1 92/4885 |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | UPF1, NSUN2, RNMT | HPSE 1899/4885HSPD1 1387/4885HSPE1 1439/4885 |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, NSUN2, SNRPB2 | HPSE 2578/4885HSPD1 1324/4885HSPE1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.